ADVANCES IN SYSTEMIC TREATMENT OF NAOPHARYNGEAL CARCINOMA

    loading  Checking for direct PDF access through Ovid

Abstract

With high local control rates achieved by the use of intensity modulated radiotherapy (IMRT) in NPC, the challenge is to improve distant control by systemic therapies. The current standard of care for stages IIB and above NPC is concurrent cisplatin–IMRT with or without adjuvant cisplatin–5FU. Neoadjuvant chemotherapy followed by chemoradiotherapy (CRT) is being investigated in ongoing randomized phase III trials. Platinum-based doublet chemotherapy is standard first-line therapy in metastatic disease. Molecular therapies targeting EGFR, VEGF, P13K-AKT-mTOR pathways, as well as epigenetic and immunotherapeutic approaches are promising and an overview of ongoing studies will be presented.

Related Topics

    loading  Loading Related Articles